Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use
NCT06513156 · View on ClinicalTrials.gov ↗
Study Summary
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
Conditions Studied
Interventions
- BEHAVIORAL Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
Study Locations (4)
District of Columbia
- George Washington University — Washington D.C.
Georgia
- Emory University — Atlanta
Maryland
- University of Maryland Baltimore — Baltimore
West Virginia
- West Virginia University — Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2027-07-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06513156
The ClinicalTrials.gov registry entry for NCT06513156 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elana Rosenthal, which has 28 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention — of which Integrated Infectious Diseases and Substance Use Disorder Clinic (IC) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06513156 reports 4 study locations spanning 4 distinct geographic areas — top geographies include District of Columbia, Georgia, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06513156 about?
NCT06513156 is a clinical study titled "Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use". This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improv...
What is the current status of trial NCT06513156?
This trial is currently recruiting. It is a NA study. The enrollment target is 304 participants. The study started on 2024-10-01. Estimated completion is 2027-07-30.
What conditions does trial NCT06513156 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Stimulant Use Disorder, Injection Related Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06513156?
The interventions under investigation include: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC) (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06513156?
This trial is sponsored by Elana Rosenthal, which has 28 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06513156 being conducted?
This trial has 4 study locations across District of Columbia, Georgia, Maryland, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.